Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Enhancing immune responses with immune-modulatory monoclonal antibodies directed to inhibitory immune receptors is a promising modality in cancer therapy. Clinical efficacy has been demonstrated with antibodies blocking inhibitory immune checkpoints such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or PD-1/PD-L1. Treatment with ipilimumab, a fully human CTLA-4-specific mAb, showed durable clinical efficacy in metastatic melanoma; its mechanism of action is, however, only partially understood. This is a study of 29 patients with advanced cutaneous melanoma treated with ipilimumab. We analyzed peripheral blood mononuclear cells (PBMCs) and matched melanoma metastases from 15 patients responding and 14 not responding to ipilimumab by multicolor flow cytometry, antibody-dependent cell-mediated cytotoxicity (ADCC) assay, and immunohistochemistry. PBMCs and matched tumor biopsies were collected 24 h before (i.e., baseline) and up to 4 wk after ipilimumab. Our findings show, to our knowledge for the first time, that ipilimumab can engage ex vivo FcγRIIIA (CD16)-expressing, nonclassical monocytes resulting in ADCC-mediated lysis of regulatory T cells (Tregs). In contrast, classical CD14(++)CD16(-) monocytes are unable to do so. Moreover, we show that patients responding to ipilimumab display significantly higher baseline peripheral frequencies of nonclassical monocytes compared with nonresponder patients. In the tumor microenvironment, responders have higher CD68(+)/CD163(+) macrophage ratios at baseline and show decreased Treg infiltration after treatment. Together, our results suggest that anti-CTLA-4 therapy may target Tregs in vivo. Larger translational studies are, however, warranted to substantiate this mechanism of action of ipilimumab in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Two pivotal phase III clinical trials in patients with advanced melanoma of the fully human, anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) IgG1 monoclonal antibody ipilimumab (Yervoy; previously MDX-010; Medarex/Bristol Myers-Squibb) reported significantly increased overall survival, which led to its appro…”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“CD163 is a scavenger receptor for the hemoglobin–haptoglobin complex and is typically expressed by immune-suppressive macrophages (known as M2-like) (25), which have been associated with poor prognosis in patients with early-stage melanoma (26).”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 2×
“On the contrary, CD68CD16 are classically activated, M1-like macrophages that secrete inflammatory mediators such as IL-12, TNF-α, and inducible nitric oxide synthase; exhibit antitumor activity; and elicit tumor tissue disruption (28).”
BackgroundMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 2×
“Sex Male 21 (72) Female 8 (28) ECOG performance status 0 17 (59) 1 12 (41) M stage M1a 2 (7) M1b 6 (21) M1c 21 (72) Prior lines of systemic therapy for metastatic disease 1 28 (97) 2 1 (3) Ipilimumab cycles 4 23 (79) 3 3 (10) 2 3 (10) 1 0”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 1×
“CD163 macrophages are known for secreting immune-suppressive mediators such as IL-10 and TGF-β, low tumoricidal activity, and promotion of tissue remodeling and angiogenesis (27).”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 1×
“(19, 20), postsort flow cytometric analysis confirmed that the vast majority Table 1.”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“Sex Male 21 (72) Female 8 (28) ECOG performance status 0 17 (59) 1 12 (41) M stage M1a 2 (7) M1b 6 (21) M1c 21 (72) Prior lines of systemic therapy for metastatic disease 1 28 (97) 2 1 (3) Ipilimumab cycles 4 23 (79) 3 3 (10) 2 3 (10) 1 0”
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 1×
“Sex Male 21 (72) Female 8 (28) ECOG performance status 0 17 (59) 1 12 (41) M stage M1a 2 (7) M1b 6 (21) M1c 21 (72) Prior lines of systemic therapy for metastatic disease 1 28 (97) 2 1 (3) Ipilimumab cycles 4 23 (79) 3 3 (10) 2 3 (10) 1 0”
Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S.-Y., Senechal, B., Puel, A., Biswas, S. K., Moshous, D., Picard, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.012 · Cited by 1,249
The CD14+ CD16+ blood monocytes: their role in infection and inflammation
Ziegler-Heitbrock, L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806510 · Cited by 1,041
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 11×
“More recently, studies in mice revealed that the antitumor activity of CTLA-4 blockade is mediated by Fc gamma receptor (FcγRIV)expressing macrophages in the tumor microenvironment (TME) via in trans depletion of tumor-infiltrating Tregs (8–10).”
BackgroundInfluentialViguier, M., Lemaître, F., Verola, O., Cho, M.-S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., & Ferradini, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1444 · Cited by 686
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · cited 11×
“More recently, studies in mice revealed that the antitumor activity of CTLA-4 blockade is mediated by Fc gamma receptor (FcγRIV)expressing macrophages in the tumor microenvironment (TME) via in trans depletion of tumor-infiltrating Tregs (8–10).”
BackgroundInfluentialBulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Identification and manipulation of tumor associated macrophages in human cancers
Heusinkveld, M., & van der Burg, S. H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-216 · Cited by 435
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Toward a Refined Definition of Monocyte Subsets
Ziegler-Heitbrock, L., & Hofer, T. P. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00023 · Cited by 298
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 262
Self-citationCutting Edge: Lymphoproliferative Disease in the Absence of CTLA-4 Is Not T Cell Autonomous
Bachmann, M. F., Köhler, G., Ecabert, B., Mak, T. W., & Kopf, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1128 · Cited by 235
Immunology beats cancer: a blueprint for successful translation
Pardoll, D. M. (2012) · Nature Immunology · doi:10.1038/ni.2392 · Cited by 181
Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., & Nimmerjahn, F. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.009 · Cited by 149
Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells
Wang, C. J., Kenefeck, R., Wardzinski, L., Attridge, K., Manzotti, C., Schmidt, E. M., Qureshi, O. S., Sansom, D. M., & Walker, L. S. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200972 · Cited by 85
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,546
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Metadata
- Authors
- Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E.
- Affiliations
- Ludwig Cancer Research (BE)
- Laboratory of Tumor Immunobiology,
- Centre Hospitalier Universitaire Vaudois (CH)
- Universitätsklinikum Tübingen (DE)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-04-27
- Volume
- 112
- Issue
- 19
- Pages
- 6140-6145
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4434760
- OpenAlex
- W2100228832
- Cited by
- 601
- References
- 31
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 38 · 2023: 52 · 2022: 55 · 2021: 72 · 2020: 70 · 2019: 71 · 2018: 66 · 2017: 68 · 2016: 42 · 2015: 12
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Fondation Leenaards (NA)
- Fondation Contre le Cancer (NA)
- Fondation Nuovo-Soldati (NA)
- Fondation Emma Muschamp (NA)
- SNSF Sinergia (CRSII3_141879)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- ipilimumab, CTLA-4 blockade, regulatory T cells, non-classical monocytes, FcγRIIIa, antibody-dependent cellular cytotoxicity, melanoma, tumor microenvironment, immune checkpoint inhibitors, treatment response
- MeSH terms
- Ipilimumab, CD68 Molecule, Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Cell Separation, Female, Flow Cytometry, Gene Expression Regulation, Humans, Immunohistochemistry, Macrophages, Male, Melanoma, Middle Aged, Skin Neoplasms, Antigens, Differentiation, Myelomonocytic, Antigens, CD, CD3 Complex, Receptors, IgG, Lipopolysaccharide Receptors, T-Lymphocytes, Regulatory, Mice, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.